The news is directly related to Apyx Medical (APYX) as JMP Securities analyst David Turkaly maintains the Market Perform rating for the company. This rating suggests that the stock is expected to perform in line with the market, and it does not indicate any significant change in the short term. Therefore, the short term impact on the stock price is neutral.